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Summary
The molecular mechanism of tissue-specific metastasis in tumors endogenously expressing members of the vascular
endothelial growth factor (VEGF) family is not yet clear. Here we demonstrate that MMP9 is specifically induced in premeta-
static lung endothelial cells and macrophages by distant primary tumors via VEGFR-1/Flt-1 tyrosine kinase (TK) and that
it significantly promotes lung metastasis. In a genetic approach using mice, suppression of MMP9 induction by deletion
of either VEGFR-1TK or MMP9 markedly reduced lung metastasis. Furthermore, the MMP9 levels in endothelial cells of
normal lung lobes from patients carrying distant tumors were significantly elevated as compared with those from patients
without tumors. Thus, a block of MMP9 induction via VEGFR-1 inhibition could be useful for the prevention of tumor
metastasis in lung.
Introduction other cell types were recently reported to express VEGFR-1
(Gerber et al., 2002; Hattori et al., 2002).
VEGFR-2 is a major positive signal transducer for angiogen-Vascular endothelial growth factor (VEGF) and its receptor
(VEGFR) family including VEGFR-1 (Flt-1), VEGFR-2 (KDR/ esis through its strong tyrosine kinase activity. VEGFR-1 has
unique biochemical activity with a 10-fold higher affinity to VEGFFlk-1), and VEGFR-3 (Flt-4) are well known to be a crucial regula-
tory system for normal and pathological angiogenesis (Musto- than VEGFR-2 but with much weaker tyrosine kinase activity
(Park et al., 1994; Mustonen and Alitalo, 1995; Seetharam etnen and Alitalo, 1995; Ferrara and Davis-Smyth, 1997; Risau,
1997; Shibuya, 2001). VEGFR-1 (as well as VEGFR-2 and al., 1995; Sawano et al., 1996, 1997; Ferrara and Davis-Smyth,
1997; Takahashi et al., 1999). We previously showed usingVEGFR-3) is structurally related to the Fms/Kit/PDGFR family
and contains an extracellular domain carrying seven immuno- VEGFR-1TK/ mice that VEGFR-1 has a dual function in angio-
genesis, acting in a positive or negative manner under differentglobulin (Ig)-like sequences and a cytoplasmic tyrosine kinase
domain with a long kinase insert. VEGFR-1 is expressed as a biological conditions. VEGFR-1 has a negative regulatory func-
tion for physiological angiogenesis in the embryo, possibly withfull-length tyrosine kinase receptor and in some cases as a
soluble form that carries only the extracellular domain (Shibuya its strong VEGF-trapping activity (Hiratsuka et al., 1998).
In solid tumor angiogenesis, nutrition supplied by bloodet al., 1990; Matthews et al., 1991; Terman et al., 1992; Kendall
and Thomas, 1993; Kondo et al., 1998). VEGFR-1 and VEGFR-2 vessels is necessary for growth once the tumor is over a few
millimeters in diameter (Folkman, 1992; Hanahan and Folkman,are specifically expressed on vascular endothelial cells (Jake-
man et al., 1992; Eichmann et al., 1993; Kaipainen et al., 1993; 1996). VEGFR-1 can also act as a potential positive regulator
using its tyrosine kinase during tumor angiogenesis when theQuinn et al., 1993; Yamane et al., 1994). As an exception, the
VEGFR-1 mRNA has been shown to be expressed in mono- VEGFR-1-specific ligand is expressed at abnormally highly lev-
els (Hiratsuka et al., 2001). However, in the case of spontaneouscytes/macrophages, which are involved in the migration toward
VEGF (Barleon et al., 1996; Clauss et al., 1996). In addition, metastasis, the metastatic tumors in the wild-type grew faster
S I G N I F I C A N C E
The mechanism of tissue-specific tumor metastasis is still not clearly elucidated. Here we propose a crucial role for the VEGF-receptor/
MMP system not only in angiogenesis but also in tumor metastasis via a novel mechanism. We demonstrate that the primary
tumors themselves determine the specific site of metastasis by selectively inducing MMP9 expression in lung endothelial cells and
macrophages, thereby promoting the invasion of tumor cells, preferentially to the lung. The induction of MMP9 expression is dependent
on the VEGFR-1 tyrosine kinase. This study also suggests that macrophages play an important role in the upregulation of MMP9
expression in lung endothelial cells. Thus, more preventable medication for lung metastasis could be possible by VEGFR-1 tyrosine
kinase inhibitor and MMP inhibitor.
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than in VEGFR-1TK/ mice in spite of no significant difference Our system is similar to that, but one step improved, since we
used tumor-bearing mice as well as healthy mice for tumor cellin the growth rate of the primary tumors between the two geno-
types. This raised an intriguing possibility that the difference colonization in the variety of tissues. One merit of this “experi-
mental” metastasis model is that we could use a fixed numbermight be due to a difference in tumor migration or tumor invasion
that was not directly related to the tumor angiogenic phase. of tumor cells for i.v. injection, and thus we could simply ask the
difference or similarities on the latter half of metastatic processMatrix metalloproteinases (MMPs), which can degrade ex-
tracellular matrix components, play a critical role in tissue re- (colonization and growth of tumor cells in the tissues).
MMP9 was specifically induced in the lungs of tumor-bearingmodeling during development in pathological process, including
inflammation, tissue repair, tumor invasion, and metastasis wild-type but not VEGFR-1TK/ mice. To determine whether
any factors linked to VEGFR-1 might have an effect on the(Stetler-Stevenson, 1999; Egeblad and Werb, 2002). Recently,
MMPs such as MMP9/gelatinaseB, MMP2/gelatinaseA, MMP3/ premetastatic lungs, we examined lung tissues obtained from
wild-type and VEGFR-1TK/ mice with or without LLC tumorsstromelysin1, and MMP7/matrylysin have emerged as regula-
tors of angiogenesis and tumor progression (Brooks et al., 1996; implanted subcutaneously on their backs. Lung tissues were
histologically indistinguishable among the normal wild-type andWilson et al., 1997; Cockett et al., 1998; Itoh et al., 1998; Vu et
al., 1998; Sternlicht et al., 1999; Coussens et al., 2000). Among the tumor-implanted wild-type and VEGFR-1TK/ mice (data
not shown). To identify the candidate molecules that play keyMMPs, MMP9 is of particular interest, because it is thought to
be a tumor angiogenic factor that signals through the VEGF- roles in lung metastasis, we next examined the gene expression
in various tissues, including lung, for VEGFR-1-related ligands,VEGFR system (Bergers et al., 2000). In the present study, we
have focused on the MMP9 expression in a target organ during VEGF-R family, MMPs, TGF- (Gohongi et al., 1999), and others.
As shown in Figure 1F, among MMPs, MMP9 expression wasthe premetastatic phase and have demonstrated that an eleva-
tion of MMP9 in the premetastatic lung by a distant primary specifically increased in the lungs of wild-type mice after tumor
implantation. Moreover, this increase was dependent on thetumor is dependent on the tyrosine kinase of VEGFR-1 and that
this elevation promotes lung metastasis. tyrosine kinase of VEGFR-1, since the MMP9 expression in
VEGFR-1TK/ mice carrying LLC tumors was not elevated.
We also analyzed various MMPs at protein levels and con-Results
firmed that only the MMP9 protein was elevated in the tumor-
bearing wild-type mice (data not shown). Therefore, we nextMMP9 induction in lung stimulated by a distant primary
tumor depends on the tyrosine kinase of VEGFR-1 examined whether MMP9 has a critical role in determining the
lung-specific metastasis of tumor cells.The growth rate of lung metastatic tumors is different between
the wild-type and VEGFR-1TK/ mice. We previously showed To assess whether other tumor cell lines also stimulate the
lung MMP9 level from a distant site in vivo, we used gelatinthat the growth rates of Lewis lung carcinoma (LLC) and mela-
noma (B16) in primary subcutaneous sites were not significantly zymography to check the lung tissues of nude mice carrying
various tumors. Figure 2A shows that melanoma, colon cancerdifferent between wild-type and VEGFR-1TK/ mice (Hiratsuka
et al., 2001). Similarly, implanted highly spontaneous metastatic (C26), Ehrlich tumor, and angioma (F2) implanted subcutane-
ously induced an increase of pro-MMP9 in lung, a proenzyme3LL-LLC (3LL) tumors exhibited indistinguishable growth rates
in primary sites between the two genotypes. However, the num- form of MMP9. No induction of MMP9 was found in livers,
kidneys, or spleens, although the spleens consistently carriedber of spontaneous metastatic tumor nodules in the lungs of
the wild-type was found to be 3-fold higher than that in VEGFR- pro-MMP9 possibly derived from macrophages.
To confirm that the upregulation of lung MMP9 by primary1TK/ mice (Figures 1A and 1B). Since no significant difference
in the lung metastasis was found between the two genotypes tumors depends on the tyrosine kinase of VEGFR-1, we used
LLC and B16 melanoma (B16) cells that can be implanted inwhen LLC cells were directly injected intravenously into mice
without primary tumors (Figure 1C), we hypothesized that dis- the genetic background of VEGFR-1TK/ mice. As shown in
Figure 2B, the pro-MMP9 in premetastatic lungs from wild-typetant primary tumors have a crucial effect on premetastatic lung
tissues via tyrosine kinase of VEGFR-1. To separate the premet- mice was three to five times higher than that from VEGFR-
1TK/ mice. An activated form of MMP9 was also induced atastatic phase from the lung metastatic phase, we replaced the
highly metastatic 3LL-LLC cells with a LLC cell line that lacks low levels in tumor-bearing wild-type mice but not in tumor-
bearing VEGFR-1TK/ mice. These primary tumors did notspontaneous metastatic ability but elicits metastasis after intra-
venous injection. We detected fluorescence-stained tumor cells stimulate another gelatinase, MMP2 in lungs (Figure 2B). Even in
the spontaneous metastatic situation using 3LL-LLC, the MMP9only in primary tumor tissues but not in lungs for up to 1.5
months. In addition, no PCR products for the vector sequence induction occurred at very early stage, possibly prior to lung
metastasis, at day 12 (Figure 2C).inserted into tumor cells were found in the lungs (Figure 1D),
indicating that there were no detectable micrometastases to VEGF and PlGF stimulated lung MMP9 through VEGFR-1
in organ culture. Both LLC and B16 tumors express VEGF andlungs.
As an experimental model, we defined the premetastatic VEGF-B, ligands for VEGFR-1 (Hiratsuka et al., 2001). Therefore,
we next examined whether VEGF could stimulate MMP9 expres-phase as a period until the implanted LLC had grown to 1.5 cm in
diameter at subcutaneous sites. Alternatively, for the metastatic sion through the tyrosine kinase of VEGFR-1 using an organ
culture system in vitro. Addition of exogenous VEGF or placentaphase, we intravenously injected LLC cells into the tumor-bear-
ing mice to examine the organs that the tumor cells prefer to growth factor (PlGF), a ligand specific for VEGFR-1 (Maglione
et al., 1991; Kendall and Thomas, 1993; Sawano et al., 1996;invade (Figure 1E).
Lung colonization of tumor cells injected through the tail Barleon et al., 1997), into the organ culture medium increased
the induction of MMP9. However, VEGF-E (Ogawa et al., 1998),vein is widely used as a model system for detecting metastasis.
290 CANCER CELL : OCTOBER 2002
A R T I C L E
Figure 1. Induction of lung MMP9 in tumor-bearing wild-type (F) but not in VEGFR-1 TK/ (FTK) mice
A–C: Tumor growth rates in primary sites (A) and spontaneous lung metastasis (B) in 3LL-LLC-bearing mice. Lung metastasis of LLC without primary tumors
(C). Student’s t test, p  0.01. D: Top: No metastases were detected from primary tumors to the lungs in wild-type or VEGFR-1TK/ mice. Fluorescence-
stained, retrovirus vector-inserted LLC and B16 cells were detected in tumor tissues but not in the lungs on day 14. The bar equals 100 m. Bottom: No
bands were found in the lungs from normal (lanes 1–3), LLC-bearing (lanes 4–6), or B16-bearing (lanes 7–9) mice using PCR analysis. Lung tissues containing
tumor cells (lane 10, 100 cells; lane 11, 50 cells; lane 12, 0 cell) were used as a positive control. E: An experimental metastatic model. Premetastatic phase
is the period of tumor growth at a primary site. Metastatic phase is the period after intravenous tumor cells injection. F: Screening of genes in various tissues
and tumors obtained from LLC-bearing wild-type (FL) and VEGFR-1TK/ (FTKL) mice.
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Figure 2. Reduced induction of lung MMP9 in tumor-bearing VEGFR-1TK/ mice using gelatin zymography
A: Various tissues were obtained from Angioma (F2), colon cancer (C26), Ehrlich tumor (E), melanoma (B16), or LLC-bearing nude mice. B: MMP9 in wild-
type (F), VEGFR-1TK/ (FTK), LLC-bearing wild-type (FL) and VEGFR-1TK/ (FTKL), and B16-bearing wild-type (FB) and VEGFR-1TK/ (FTKB) mice. C:
MMP9 in the lungs of 3LL-LLC-bearing mice. D: Organ culture with the VEGF family. Specimens of lungs were cultured with VEGF for 1, 2, or 3 days.
Additionally, lung tissues were cultured with PlGF2 or VEGF-E for 2 days.
which is a specific ligand for VEGFR-2, did not stimulate MMP9 from tumor-bearing wild-type mice but not from others. Consis-
in the lungs of either genotype (Figure 2D). TGF- and TNF, tently, the proteolytic activity of MMP9 was also found in these
expressed in LLC and B16 tumors, slightly stimulated MMP9, cells from tumor-bearing wild-type mice, but it was only faint
but not in a VEGFR-1-dependent manner (data not shown). in those from tumor-bearing VEGFR-1TK/ mice (Figure 3B).
These results indicate that the lung MMP9 could be induced by Moreover, the purified lung endothelial cells expressed VE-
VEGF or PlGF signaling through the tyrosine kinase of VEGFR-1 cadherin in both genotypes, but MMP9 was detectable only in
but not VEGFR-2 in vitro. tumor-bearing wild-type mice by immunohistochemistry (Fig-
ure 3C).
Macrophages cooperate in the endothelial MMP9 To analyze the relationship between the MMP9 induction in
induction endothelial cells and the primary tumor-activated macrophages,
To define the cells in which MMP9 was induced by primary we cocultured these cells in vitro for 2 days. Wild-type lung
tumors, we examined lung tissues by immunohistochemistry endothelial cells cultured on the alveolar macrophages obtained
using an anti-mouse MMP9 antibody. We found that the MMP9 from tumor-bearing wild-type mice highly expressed MMP9. In
was induced in endothelial cells, as characterized by the mouse
contrast, the same endothelial cells of wild-type on the macro-
CD31 (data not shown) and VE-cadherin staining, in tumor-
phages from tumor-bearing VEGFR-1TK/ mice showed little
bearing wild-type but not VEGFR-1TK/ mice (Figure 3A). In
MMP9 induction (Figure 4). The macrophages at lower layeraddition, the numbers of Mac1-MMP9 double-positive lung
expressed some amounts of MMP9 (see Figure 4 legend). Thesemacrophages were 1.5- to 2-fold higher in tumor-bearing wild-
results suggest that primary tumors induce endothelial celltype mice than those in tumor-bearing VEGFR-1TK/ mice
MMP9 through an interaction between endothelial cells and(Figure 3A, bottom, and Table 1).
lung macrophages via a VEGFR-1-dependent mechanism.For further analyses, we collected lung endothelial cells us-
The number of macrophages carrying MMP9 increased 3-ing anti-mouse CD31 antibody beads. By staining, these CD31-
to 4-fold in the tumor-bearing wild-type mice compared to thosepositive cells included 93% of VE-cadherin-positive cells and
in healthy mice (Table 1), and the lung endothelial cells in theabout 7% of Mac1-positive cells (data not shown). These cells
same tumor-bearing mice upregulated MMP9 in cooperationexpressed VEGFR-2, a marker for endothelial cells, but neither
with macrophages (Figures 3 and 4). Based on these resultsVEGF- nor PDGF-receptor, markers for epithelial cells and
and the proportion of macrophages and endothelial cells in thesmooth muscle cells, respectively, using RT-PCR. The MMP9
mRNA was expressed in these CD31-positive cells specifically lung, we suggest that about one-half of MMP9 increase in the
292 CANCER CELL : OCTOBER 2002
A R T I C L E
Figure 3. Suppression of lung MMP9 in endothelial cells and macrophages from tumor-bearing VEGFR-1TK/ mice
A: Immunohistochemistry of lung tissue from B16-bearing wild-type (FB) or VEGFR-1TK/ (FTKB) mice using anti-VE-cadherin, anti-MMP9, or anti-Mac1
antibody. VE-cadherin (FITC), Mac1 (FITC), and MMP9 (Rhodamin) signals were detected by using fluorescence microscope. Overlapped figure of nuclear
staining (DAPI) with Nomarski. Normal rat or rabbit IgG-stained sections were shown as negative control (bottom right). The bar equals 50 m. B: RT-PCR
analysis of lung CD31-positive cells collected from wild-type and VEGFR-1TK/ mice implanted with normal, LLC, or B16 cells (top). Gelatin-substrate
zymography of lung CD31-positive cells also indicates the suppression of MMP9 induction in tumor-bearing VEGFR-1TK/ mice (bottom). C: MMP9 in lung
CD31-positive cells (93% VE-cadherin-positive, 7% Mac1-positive cells). VE-cadherin-positive cells (endothelial cells) express a high level of MMP9 in B16-
bearing wild-type (FB) but not in VEGFR-1 TK/ (FTKB) mice. The bar equals 50 m.
Table 1. The numbers of MMP9- or Mac1-positive cells in lung tissues
Genotypes of mice with (LLC or B16) or MMP9- Mac1-positive
without tumors (norm) positive cellsa cells (/mm2)
Flt-1TK/(FTK)-norm 28  2b 30  2
Wild (F)-norm 30  2 33  2
FTK-LLC 68  7c 78  7c
F-LLC 122  18 175  11
FTK- 61  5c 62  5c
F-B16 92  7 114  8
Flt-1TK//MMP9/mice (FTKM)-norm 0 43  2
Flt-1TK//MMP9/mice (FM)-norm 0 44  3
Flt-1TK//MMP9/mice (FM)-norm 39  4 41  3
FTKM-LLC 0 95  8c
FM-LLC 0 198  6
FM-LLC 161  13 207  21
FTKM-B16 0 51  2c
FM-B16 0 100  9
FM-B16 85  9 120  19
The cells were counted from one out of five sections per one mouse. Three mice of each genotype were used for the analysis.
a MMP9-positive cells except for endothelial cells. Most of the MMP9-positive cells were Mac1-positive cells (Macrophage-like cells).
b Mean  S.D.
c Significantly different from tumor-bearing wild-type mice. p  0.05.
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cells in the lungs of tumor-bearing wild-type mice was three
times higher than that of the other three groups including wild-
type without primary tumors and VEGFR-1TK/ mice with or
without primary tumors (Figure 5A). In contrast, the number of
tumor cells that had invaded other tissues such as liver, spleen,
and kidney were essentially the same in tumor-bearing mice of
both genotypes, and these cells were unable to proliferate from
the small colonies by day 7 (Figure 5A).
Furthermore, to assess whether VEGFR-1-dependent lung
MMP9 induction by primary tumors has any direct effects on
metastasis in vivo, we adopted a genetic approach, utilizing
mice carrying disruptions of the VEGFR-1TK and/or MMP9
genes (Itoh et al., 1999). We investigated lungs from the premet-
astatic and metastatic phases in wild-type (FM), VEGFR-
1TK//MMP9/ (FM), and VEGFR-1TK//MMP9/
(FTKM) mice using the same strategy as above. Since no differ-
ence in the growth rates of the primary tumors was found among
FM, FM, and FTKM mice, we were able to examine the
invasion phenotype without the need to consider differences in
size of primary tumors. To monitor the metastatic phase, we
injected fluorescence-marked tumor cells from the tail vein into
FM, FM, and FTKM mice in which tumors had already
been implanted on their backs. Interestingly, the number of
tumor cells in the lungs from tumor-bearing FM mice signifi-
cantly decreased compared to FM mice on day 2 after i.v.
injection (Figure 5B). These results suggest that the elevation
of MMP9 stimulated by the primary tumors is a key regulator
of lung metastasis.
MMP9 and VEGFR-1 upregulate the invasion
of tumor cells in vitro
To examine tumor cell invasion to the lung more directly and
to avoid any uncertain factors in vivo, we developed a simple
in vitro system for the migration of tumor cells into a thin slice
of lung tissues from mice with or without tumors. To easily
measure the number of cells that invaded the lung specimens,
we used LLC and B16 tumor cells carrying a retrovirus vector
that could be detected by PCR analysis in this chemotaxis assay
(Figure 6A). Stronger PCR bands reflecting a greater number of
invading tumor cells were found in lung tissues from tumor-
Figure 4. MMP9 induction in lung endothelial cells is cooperatively regulated bearing wild-type mice compared to those from tumor-bearing
by macrophages via VEGFR-1 in vitro VEGFR-1TK/ mice (Figure 6B, top). These invasions were
A: Endothelial cells (EC) from normal wild-type (F) or VEGFR-1TK/ (FTK) inhibited to basal levels by 100 M batimastat (BB94), a MMP
mice cocultured with alveolar macrophages (Mφ) from B16-bearing mice
inhibitor (Figure 6B, top; Prontera et al., 1999). We also detected(FB or FTKB). Endothelial cells were plated on the macrophage layer and
more intensive bands in tumor-bearing FM mice than in tu-further cultured in a medium containing 10 ng/ml VEGF for 2 days (see
Experimental Procedures). The bar equals 20 m. B: Summary of the MMP9 mor-bearing FM and FTKMmice, indicating that the invasion
quantification in endothelial cells. The signal intensities of macrophage of tumor cells into lung tissues in vitro depends on the amount
MMP9 ranged from 50 to 60 arbitrary units. Mean  S.D. (Student’s t test, of MMP9 induced in lung (Figure 6B, bottom).p  0.01)
Human MMP9 of endothelial cells is upregulated in lung
tissues from patients with various tumors
To assess whether distant primary tumors stimulate the lunglung (Figure 2B) is derived from endothelial cells and another
endothelial cell MMP9 in humans, we examined the expressionhalf from macrophages.
of MMP9 in healthy regions of lung from patients who carried
tumors in other organs apart from the lungs. At first, we micro-MMP9 regulates lung-specific metastasis
scopically checked lung lobes to obtain healthy regions withoutvia VEGFR-1
tumor metastasis, atelectasis, or inflammation. As a control, weTo address the functional significance of the VEGFR-1 tyrosine
detected very low levels of MMP9 in VE-cadherin-positive lungkinase-dependent stimulation including MMP9 induction on
endothelial cells from patients without tumors. In contrast, inten-lung metastasis, we monitored fluorescence-marked tumor cells
sive staining of MMP9 on endothelial cells was found in lunginjected intravenously into the tumor-bearing mice. Remarkably,
2 days after the i.v. injection, the number of metastatic tumor tissues obtained from patients with tumors, such as hepatocel-
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Figure 5. Decreased infiltration of injected tumor
cells into lung in tumor-bearing VEGFR-1TK/ or
MMP9/ mice
A: Number of invaded tumor cells on day 2, 7,
and 14 after i.v. injection into normal wild-type
(F), VEGFR-1TK/ (FTK), tumor-bearing wild-
type (FL or FB), and tumor-bearing VEGFR-
1TK/ (FTKL or FTKB) mice. Before assay, blood
was replaced to PBS () to avoid a contamina-
tion of tumor cells in blood. B: Number of invaded
tumor cells in lung on day 2 and 14 after i.v.
injection of fluorescence-stained LLC or B16 cells
into normal or tumor-bearing VEGFR-1TK//
MMP9/ (FTKM), VEGFR-1TK//MMP9/
(FM), and VEGFR-1TK//MMP9/ (FM)
mice. Fluorescence-stained cells were counted
from ten sections per tissue. Mean  S.D. (Stu-
dent’s t test, p  0.05, p  0.01, p  0.005).
lular carcinoma, pancreatic cancer, esophageal cancer, colon vessels to secondary sites, proliferation supported by the meta-
static environment, and tumor growth over a few millimeterscancer, cholangiocellular carcinoma, gastric cancer, malignant
melanoma, malignant lymphoma, and ovarian cancer (Figures in diameter with angiogenesis (Folkman, 1992; Hanahan and
Folkman, 1996). The organ preference of metastasis is estab-7A–7N). We calculated the average MMP9 intensities of lung
endothelial cells stained with an anti-human MMP9 antibody to lished by original migration and invasion of tumor cells to spe-
cific metastatic sites (Nicolson, 1993; Yeatman and Nicolson,compare between patients with and without tumors. A signifi-
cant difference was found in the intensity of MMP9 per single 1993). Although some molecules have been considered as can-
didates governing the organ preference in the chemotaxis andendothelial cell between tumor-bearing (90  17, mean 
S.D.) and non-tumor-bearing (19  3) patients (Figure 7O). Fi- chemoinvasion (Nicolson, 1993), it has been an open question
as to whether any cytokines from the primary tumors mightnally, we detected a few small metastatic nodules in lung lobes
other than the examination sites in 77% of patients with primary have an effect on the organ specificity of metastasis.
Chemokine ligands and receptors, the chemotactic factorstumors.
preexisting in target organs and tumor cells, have recently been
reported to decide the organ preference at the phase of migra-Discussion
tion to the target organs (Muller et al., 2001). On the other hand,
cytokines secreted from primary tumors are capable of effectingMetastasis is the result of many sequential steps, such as migra-
tion from primary sites to blood or lymphatic vessels, nonran- distant metastatic sites because several factors such as angio-
statin (O’Reilly et al., 1994), endostatin (O’Reilly et al., 1997),dom chemotaxis to preferential target organs, invasion from
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Figure 6. Reduced invasion of tumor cells into lung tissues from tumor-bearing VEGFR-1TK/, MMP9/, or VEGFR-1TK//MMP9/ mice in vitro
A: Scheme of the invasion assay. B: Semiquantitative PCR analysis for invasion of tumor cells. Lung specimen from normal as well as LLC or B16 tumor-
bearing wild-type (F) and VEGFR-1TK/ (FTK) mice were used. DMSO is negative control for BB94 (top). Lung tissues from normal VEGFR-1TK//MMP9/
(FTKM), VEGFR-1TK//MMP9/ (FM), and VEGFR-1TK//MMP9/ (FM) mice as well as tumor-bearing FTKM, FM, and FM mice were used. For
the PCR positive control, 0, 100, and 200 LLC cells plus lungs were used (bottom).
and TGF- (Gohongi et al., 1999) from primary tumors nonspe- MMP9 specifically in lungs but not in livers from organ cultures
in vitro.cifically inhibited angiogenesis in metastatic sites.
Now, we have shown that the tumors themselves aggres- Our preliminary result using RT-PCR showed that VEGFR-1
is more highly expressed in purified lung endothelial cells thansively determine a specific metastatic site by selectively induc-
ing an invasive factor in a distant premetastatic site. More spe- in those of liver, indicating that MMP9 might be more inducible
in lungs than other organs because of the difference in signalingcifically, the MMP9 induced by primary tumors in lung
endothelial cells and macrophages promotes the invasion of through VEGFR-1. Moreover, as indicated in Figure 4, primary
tumor-stimulated lung macrophages could efficiently cooperatetumor cells preferentially into the lung tissue, and this MMP9
induction was dependent on the VEGFR-1 tyrosine kinase. Our with endothelial cells to upregulate MMP9 via VEGFR-1 at least
in vitro. Thus, we think that the lung has unique conditionsresults also suggest that macrophages play an important role
in the MMP9 upregulation in lung endothelial cells. where the activated macrophages and endothelial cells closely
interact and activate each other in tumor-bearing mice.
The MMP9-induced lung is the target of circulating
tumor cells MMP9 elevation in lung endothelial cells of patients
with primary tumorsThe VEGF-VEGF receptor system is a strong angiogenic factor
during tumor angiogenesis (Ferrara and Davis-Smyth, 1997; Shi- We have shown that MMP9 protein was increased 4.5-fold in
normal lung endothelial cells of all patients who carried primarybuya, 2001). In addition, we have shown that premetastatic sites
without angiogenesis are stimulated by primary tumors through tumors in organs other than the lungs as compared to those of
patients without tumors. This result indicates that the primarythe ligand-receptor system of the VEGFR-1 pathway. Many tu-
mors express VEGF and VEGF-B as well as PlGF occasionally tumors might stimulate MMP9 in the premetastatic lung in hu-
man. Furthermore, metastasis to a few lung lobes was actually(Hatva et al., 1996; Luo et al., 1998; Olofsson et al., 1998;
Salven et al., 1998; Donnini et al., 1999). Although cytokines found in 77% of patients with primary tumors. We can rule out
the possibility that these small lung metastatic nodules mightare secreted from primary tumors in serum, only lung endothelial
cells had the ability to induce MMP9 secretion in vivo. At first, cause MMP9 induction in other lung lobes because it was re-
ported that MMP9 expression was absent in neighboring nontu-we examined the expression of the VEGF family in lungs derived
from mice with and without tumors. However, no clear induction moral parenchyma in the presence of existing primary tumors
without distant metastasis in the lung (Nawrocki et al., 1997).of any VEGF family member was found in lungs under stimula-
tion by primary tumors. Accordingly, we supposed that the re- These data support the theory derived from the mouse model
that primary tumors induce MMP9 in lung to increase the chancesponse to the VEGF family in endothelial cells might vary among
endothelial cells from different organs, because VEGF induced of metastasis. However, it remains to be established which
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Figure 7. Increased MMP9 in endothelial cells from patients with various tumors
A–N: Immunohistochemistry of anti-VE-cadherin (A and D) and anti-MMP9 antibodies (B, E, G–N) in lung tissues of non-tumor-bearing (A–C and G–J) and
tumor-bearing (D–F and K–N) patients. Representative staining is shown in tissues from eight patients (G–N). The bars equal 50 m (A–F) and 10 m (G–N).
O: Summary of the MMP9 quantification in endothelial cells. Lung tissues from patients with no tumors and patients with various tumors. MeanS.D. (Student’s
t test, p  0.0001)
Cellstypes and stages of human primary tumors efficiently raise the
Tumor cells used are 3LL-LLC, high-metastasis type mouse Lewis lungMMP9 levels in lung.
carcinoma; LLC, no metastasis type (from s.c. transplantation); B16, no
Anticancer drugs could be safer and more effective by se- metastasis variant (from s.c. transplantation) mouse melanoma; F2, mouse
lecting a metastatic target organ. The results presented in Fig- angioma; and C26, mouse colon cancer.
ures 5 and 6B suggest that more effective approaches to prevent
RT-PCR analysislung metastasis could be developed by combination of a
Total RNA from homogenized tissue samples was extracted and reverseVEGFR-1 TK inhibitor and/or an MMP9 inhibitor.
transcribed using mouse-specific primers. Specific primers for MMP2,
MMP11, MMP13, MT1-MMP, MT2-MMP, TIMP-1, TIMP2, VEGFR-1 (N),
Experimental procedures VEGFR-1 (K), VEGF, and -actin were designed as previously described
(Hiratsuka et al., 1998; Luo et al., 1998; Kim et al., 2000). In addition, the
Animals appropriate primers were used to amplify MMP3, MMP7, MMP9, MMP10,
Generation of the VEGFR-1TK homozygous null animals whose genetic MMP12, MT3-MMP, uPA, uPA-R, PlGF, VEGF-B, TGF-, and VEGFR-2.
background is 50% of 129 and 50% of C57BL/6 mice has been reported
previously (Hiratsuka et al., 1998). MMP9 homozygous null mice (Itoh et al., Tumor cell labeling and metastasis assay in vivo
1999) were bred for five generations into C57BL/6 before intercrossing with Lewis lung carcinoma (LLC) and B16 melanoma (B16) cells were double
VEGFR-1TK/ mice. The litters of all genotypes derived from the crossing marked by infecting with a murine pSRaMSVtk-neo retrovirus vector and by
of VEGFR-1TK/ and MMP9/ mice were almost indistinguishable pheno- labeling with a PKH26 fluorescent staining kit (Zynaxis). For the metastasis
assay, 1 105 B16 or LLC cells labeled with fluorescence were intravenouslytypically and histologically.
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injected at 2 or 3 weeks after the subcutaneous implantation of 1  107 blood vessel disorders such as diabetes (Jin et al., 2001) and athrosclerosis
were also excluded.tumor cells into the mouse back. At the time points indicated, the lungs
were collected from the mice after perfusion to eliminate circulating tumor
cells. PCR analysis for the retrovirus vector sequence using a specific primer Statistical analysis
For statistical analysis, the data were expressed as mean  S.D. and werewas carried out to detect tumor cells.
analyzed using Student’s t test. A p value less than 0.05 was considered
significant.Gelatin zymography
Specimens derived from the mice were incubated in a sample buffer con-
Acknowledgmentstaining 2% sodium dodecyl sulfate (SDS) and 2% glycerol without
-mercaptoethanol at room temperature for 30 min. Samples were loaded
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Ichi Toda for F2 cells. We are also grateful to Dr. Tetsuo Noda for preparationmg/ml. Gels were washed three times in 50 mM Tris-HCl, 150 mM NaCl
of VEGFR-1TK/ mouse and Dr. Kazuki Nakao for generous support of in(pH 7.6), 10 mM CaCl2, and 5 mM ZnCl2 for more than 12 hr at 37C without
vitro fertilization technique.shaking before being subjected to Coomassie brilliant blue staining and
destaining.
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For organ culture, 2 mm2 specimens of tissue were cultured in 2% FCS- Received: July 1, 2002
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